A statin delivered into the plaque: why rosuvastatin was packed into a fat capsule

A statin lowers cholesterol across your whole bloodstream at once. But what if you could deliver it to one spot — right inside the atherosclerotic plaque, where it is needed most? That is exactly what the experimental drug YN001 is trying to do. Let us look at the idea behind it, what the first data show, and what they do not yet mean.

This article is for information only. It does not replace a consultation with your doctor and is not a prescription.

How it works

An ordinary statin pill acts throughout the body: it lowers cholesterol production in the liver, and only part of that effect reaches the plaque itself. YN001 is the same rosuvastatin, a familiar statin, but packed into a liposome. A liposome is a tiny capsule made of a fat-like material similar to the membrane of our own cells, with the drug tucked inside.

On the surface of this capsule there is an "anchor" that latches onto a protein called CD44. CD44 is abundant wherever inflammation is active — including in an unstable atherosclerotic plaque. The idea is simple: carry a familiar statin straight to the hotspot and build up a higher concentration there than a pill can, without raising the dose for the rest of the body.

One caveat up front: this is still a design being tested in a trial, not a mechanism proven in people.

What the data show

An international phase 2 trial, PURIFY-TIMI 81, is now under way. It started on 31 July 2026 and plans to enrol about 456 people with coronary atherosclerosis. Its main question is whether the volume of "soft" (non-calcified) plaque in the coronary arteries changes on CT coronary angiography over 13 weeks. This is phase 2 — a test in humans, not a final confirmation.

What came before. In an earlier programme (phases Ib/IIa) the developer reported signs of plaque shrinkage: TAV fell by 10–50% and PAV by 10–30% relative to baseline, along with a reduction of plaque in the carotid and peripheral arteries.

In plain terms: TAV (total atheroma volume) is the overall amount of plaque in the measured segment of a vessel, and PAV (percent atheroma volume) is the share of that segment the plaque occupies. Both are measured by intravascular ultrasound or by imaging.

And here is the honest caveat you cannot read those numbers without. These are early results from the company itself, largely presented at conferences, in small groups. There is as yet no large independent trial with hard outcomes — heart attacks and mortality — for YN001. In cardiology, early figures like these often fail to repeat in large trials, so they are interesting as a signal, not as proof.

What it does NOT yet mean

Today YN001 is being studied, not treating anyone. Phase 2 is not regulatory approval and not proven patient benefit. A smaller plaque volume on a scan is a surrogate marker: it is encouraging, but on its own it does not equal fewer heart attacks until that is shown in a large outcomes trial.

We rate the maturity of the evidence for YN001 at roughly 5 out of 10: an interesting idea with first human data that still has its main test ahead. Phase 2b may raise that rating — or fail to confirm the early results.

What to do about it

You cannot simply ask for YN001: it is available only within clinical trials, not from a pharmacy.

The proven way to make plaque more stable today is a different and well-known one: lower atherogenic lipoproteins consistently and deeply enough. How deeply, and with what, is a decision your doctor makes based on your numbers (LDL cholesterol, ApoB) and your overall cardiovascular risk. That is a conversation with a doctor, not a do-it-yourself choice of drug and dose.

YN001 is worth keeping on your radar as one of the directions to watch over the next year or two. If the 2b trial confirms the early signals in a large group, that will be a different conversation.

Sources

• PURIFY-TIMI 81 (phase 2b, NCT07521007), clinical trials registry — clinicaltrials.gov/study/NCT07521007